Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
July 26 2017 - 7:00AM
SAN DIEGO, July 26, 2017 (GLOBE
NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a
biopharmaceutical company advancing innovative medicines in urology
and rheumatology, today announced that Apricus' second quarter 2017
financial results will be released on Wednesday, August 2, 2017 at
4:01 p.m. Eastern Time. Company management will host a
conference call on Wednesday, August 2, 2017 at 4:30 p.m. Eastern
Time to discuss the financial results and other recent corporate
highlights.
To participate by telephone, please dial (855)
780-7196 (Domestic) or (631) 485-4867 (International). The
conference ID number is 58725002. The live audio webcast can
be accessed via the Investor Relations' section of Apricus' website
at www.apricusbio.com. Please log in approximately 5-10
minutes before the event to ensure a timely connection. The
archived webcast will remain available for 30 days following the
live call.
About Apricus Biosciences,
Inc.
Apricus Biosciences, Inc. (APRI) is a
biopharmaceutical company advancing innovative medicines in urology
and rheumatology. Apricus has two product candidates currently in
development. Vitaros is a product candidate in the United
States for the treatment of erectile dysfunction, which is
in-licensed from Warner Chilcott Company, Inc., now a subsidiary of
Allergan plc (Allergan). RayVa is our product candidate in Phase 2
development for the treatment of the circulatory disorder Raynaud's
phenomenon, secondary to scleroderma, for which Apricus owns
worldwide rights.
For further information on Apricus,
visit http://www.apricusbio.com.
Vitaros(TM) is
Apricus' trademark in the United States, which is pending
registration and subject to the agreement with Allergan.
Vitaros® is a
registered trademark of Ferring International Center S.A. in
certain countries outside of the United States.
RayVa(TM) is
Apricus' trademark, which is registered in certain countries
throughout the world and pending registration in the United
States.
CONTACT:
Institutional / Retail Investors: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Apr 2023 to Apr 2024